Live Breaking News & Updates on Anat Cohen Dayag|Page 2

Stay updated with breaking news from Anat cohen dayag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy -March 11, 2024 at 07:08 am EDT

FOR IMMEDIATE RELEASE:

Compugen Selected for two Oral Presentations at the

Keystone Symposium on Cancer Immunotherapy

. ....

Zoya Alteber , Assaf Menachem , Compugen Ltd , Oral Presentations , Keystone Symposium , Beyond Immune Checkpoint Blockade , Overcoming Resistance , Anat Cohen Dayag , Induces Potent Immune Stimulation , Anti Tumor Effects , Uniquely Expressed , Tumor Dendritic Cell Rich Niches , Memoryt Cells , Blockade May Induce Immune , Non Inflamed Tumors ,

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. ....

South Africa , Tel Aviv , Memorial Sloan Kettering Cancer Center , New York , United States , New York Presbyterian Hospital , San Francisco , Yvonne Naughton , Weill Cornell , Momenta Pharmaceuticals Inc , Corporate Communications , Therapeutics Inc , Stock Exchange , Clinical Development , Gilead Sciences , University Of The Witwatersrand , Compugen Ltd , Mount Sinai Medical Center , Aummune Therapeutics Ltd , Chief Medical Officer , Anat Cohen Dayag , Chief Executive Officer , Vice President , Momenta Pharmaceuticals , New York Presbyterian , Columbia Presbyterian ,

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled. ....

San Francisco , United States , Tel Aviv , Israel General , Yvonne Naughton , Prnewswire Compugen Ltd , Corporate Communications , Stock Exchange , Securities Exchange , Exchange Commission , Anat Cohen Dayag , Chief Executive Officer , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody . ....

Foster City , United States , Israel General , San Francisco , Tel Aviv , Flavius Martin , Compugen Ltd , Gilead Public Affairs , Securities Exchange , Gilead Sciences Inc , Tel Aviv Stock Exchange , Exchange Commission , Rights To Later Stage Development , Terms Of The Partnership , Gilead Sciences , Gilead Will Have Exclusive Rights , Later Stage Development , Protein Antibodies , Treat Various Tumor , Upfront Payment , Near Term Milestone Payment , Total Deal Value , Executive Vice President , Anat Cohen Dayag , Securities Act , Securities Exchange Act ,

Gilead gains rights to Compugen's immunotherapy programme in deal worth up to $848m

Gilead gains rights to Compugen's immunotherapy programme in deal worth up to $848m
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Flavius Martin , Gilead Sciences , Anat Cohen Dayag ,